Barclays PLC Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Barclays PLC boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 140.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 130,381 shares of the biopharmaceutical company’s stock after buying an additional 76,207 shares during the period. Barclays PLC owned approximately 0.20% of Celldex Therapeutics worth $4,431,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP lifted its stake in Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after acquiring an additional 1,167,659 shares during the period. Novo Holdings A S acquired a new position in Celldex Therapeutics during the second quarter valued at $31,458,000. Point72 Asset Management L.P. lifted its position in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after purchasing an additional 654,194 shares during the period. Marshall Wace LLP grew its position in Celldex Therapeutics by 53.3% during the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after purchasing an additional 479,068 shares during the period. Finally, Jennison Associates LLC raised its stake in shares of Celldex Therapeutics by 32.0% during the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after buying an additional 321,325 shares during the last quarter.

Celldex Therapeutics Stock Down 0.9 %

CLDX opened at $25.14 on Friday. The firm’s fifty day simple moving average is $26.79 and its two-hundred day simple moving average is $33.36. Celldex Therapeutics, Inc. has a 52-week low of $22.93 and a 52-week high of $53.18. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -9.78 and a beta of 1.57.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on CLDX shares. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Citigroup started coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci acquired 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The stock was bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.80% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.